Remarks

This Amendment is being made in response to the Notice to Comply dated March 26, 2007. Applicants respectfully submit that no new matter has been introduced.

The Commissioner is hereby authorized to charge any fees which may be required to Deposit Account No. 19-0065.

Respectfully submitted,

Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRP/kmm
Attachment: copy of Notice to Comply dated March 26, 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

COPY

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/080,772	02/22/2002	Janet K. Yamamoto	UF-267XC1	1105

23557 7590 03/26/2007
SALIWANCHIK LLOYD & SALIWANCHIK
A PROFESSIONAL ASSOCIATION
PO BOX 142950
GAINESVILLE, FL 32614-2950

RECEIVED
DRP
MAR 29 2007

EXAMINER	
PARKIN, JEFFREY S	
ART UNIT	PAPER NUMBER
1648	

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice to Comply	Application No. 10/080,772	Applicant(s) Yamamoto, J. K., *et al.*	
	Examiner Jeffrey S. Parkin	Art Unit 1648	Paper No. 03/19/2007

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☒ 7. Other: applicants are reminded that Sequences appearing in the specification and/or **drawings** (e.g., see Figures 2, 4, and 10) must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. § 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification. If the requisite SEQ ID NOS.: are not present in the sequence listing, a substitute sequence listing will be required.

Applicant May Need to Provide:

☒ An substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov.

To Download Patentin Software, visit http://www.uspto.gov/web/patents/software.htm.

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
10/080,772	02/22/2002	Yamamoto, J. K., *et al.*	UF-267XC1

EXAMINER	
Jeffrey S. Parkin, Ph.D.	
ART UNIT	PAPER NUMBER
1648	03/19/2007

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application
Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. § 1.821-1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply. Applicants are reminded that sequences appearing in the specification and/or **drawings** (e.g., see Figures 2, 4, and 10) must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. § 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification. If the requisite SEQ ID NOS.: are not present in the sequence listing, a substitute sequence listing will be required.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence

rules, 37 C.F.R. § 1.821-1.825. Failure to comply with these requirements will result in **ABANDONMENT** of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136(a). In no case may an applicant extend the period for reply beyond the **SIX MONTH** statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Please direct all replies to the United States Patent and Trademark Office via one of the following: 1) Electronically submitted through EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE); 2) Mailed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 22313-1450, Alexandria, VA 22313-1450; and 3) Hand Carry, Federal Express, United Parcel Service or other delivery service to: U.S. Patent and

Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulaney Street, Alexandria, VA 22314.

Respectfully,

Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

19 March, 2007



FIG. 2A



FIG. 2B



FIG. 2C


FC1consensus 1201 AAACCTGGTCACTTAGCTGCTAATTGCTGGCAAAGAGGTAAAAAAACCCCCGGGAAACGGGAAGATGGGGCCAGCTGC
FC1 #4
#5
#6
#10
#12
#13
#14
#15
#16
FH1 #1
#3
#10
#20
#22
#24
#41
#42
#43
AGCCCCGGTAAACCAAGTGCAGCAAATGGTGCCATCTGCACCTCCAATGGAAGACAGGAAATTGTTAGATTTATAA 1353

FIG. 2D


PC1consensus
PC1 #4
#5
#6
#10
#12
#13
#14
#15
#16
PH1 #1
#3
#10
#20
#22
#24
#41
#42
#43
STAAAAEHMYAQMGLDTRPSIKESGGKEEGPPQAYPIQTVMGAPQYVALDPKMVSIPMEKAREGLGGEEVQLMFTAFSANLTSTDMATLIMSAPGCAADK 200
PC1consensus
PC1 #4
#5
#6
#10
#12
#13
#14
#15
#16
PH1 #1
#3
#10
#20
#22
#24
#41
#42
#43
QEQMTAEVKLYLKQSLSIANANPDCKRAMSHLKPESTLEEKLRACQEVGSPGTMMQLLAEALTRVQTVQTRGSRPTCPNCKKPGHLAEQCRBAKRCNNCG 400
399

FIG. 2E


FC1consensus 401 KPGHLAANCWQRGKKTPGNGHMGPAAAPVNQVQQMVPSAPPMEDRELLDL 450
FC1 #4 P
#5
#6 400 449
#10
#12
#13
#14
#15
#16
FH1 #1
#3
#10 G
#20 G
#22
#24
#41 A
#42 A
#43

FIG. 2F


PH1
PC1
PETALUMA
UK8
PPR
SENDAI-1
BANGSTON
AOMORI-1
AOMORI-2
SENDAI-2
TM2
YOKOHAMA
SHIZUOKA
FUKUOKA
1:ATGGGGAATGGACAGGGGCGAGACTGGAAGACGGCCGTTAAGAGATGTAGTAATGTTGCTGTAGGGGTAGGGAGTAAGAGTAGAAAGTTTCGAGAAGGAA
ACTTTAGGTGGGCCATAAGGATGGCTAATGTAACTACAGGACGAGAACCTGGTGATATACCAGAGAATTTAGAACAGTTAAGATCGATTATTTGTGATTT 200
ACATGGCAGAAGAGAACAATATGGATCTAGTAAAGAAATTGATATGGCAATTACCACTTTAAAAGTTTTTGCAGTAGCTGGAATTTTAAATATGACTGTG
TCTACTGCCGCAGCAGCTGAACACATGTATGCTCAGATGGGATTAGATACCAGACCATCTATAAAAGAAGGTGGGGGAAAAGAAGAAGGACCTCCACAGG 400

FIG. 4A


PH1
PC1
PETALUMA
UK8
PPR
SENDAI-1
BANGSTON
AOMORI-1
AOMORI-2
SENDAI-2
TM2
YOKOHAMA
SHIZUOKA
FUKUOKA
401:CTTATCCTATTCAAACAGTAAATGGAGCACCACAGTATGTAGCCCTTGACCCAAAAATGGTGTCCATCTTTATGGAAAAAGCAAGAGAGGGGCTAGGAGG
TGAGGAGGTCCAACTGTGGTTCACAGCCTTTTCTGCTAATTTAACTTCAACTGATATGGCTACATTAATTATGTCTGCGCCTGGCTGTGCAGCAGATAAA 600
601:GAGATCTTAGATGAAACACTGAAACAGATGACAGCTGAGTATGATCGTACTCATCCTCCTGATGGGCCTAGACCGCTGCCCTATTTCACCGCTGCGGAGA
TTATGGGAATAGGATTAACTCAAGAACAACAAGCGGAGCCCAGATTTGCACCAGCTAGAATGCAGTGTAGAGCATGGTATCTTGAAGCACTAGGAAAGTT 800

FIG. 4B


PH1
PC1
PETALUMA
UK8
PPR
SENDAI-1
BANGSTON
AOMORI-1
AOMORI-2
SENDAI-2
TM2
YOKOHAMA
SHIZUOKA
FUKUOKA
801
1000
1001
1200

FIG. 4C


PH1
FC1
PETALUMA
UK8
PPR
SENDAI-1
BANGSTON
AOMORI-1
AOMORI-2
SENDAI-2
TM2
YOKOHAMA
SHIZUOKA
FUKUOKA
1201:AAACCTGGTCACTTAGCTGCTAATTGCTGGCAAAGAGGTAAAAAAACCCCGGGAAACGGGAAGATGGGGCCAGCTGCAGCCCCGGTAAACCAAGTGCAGC
AAATGGT***GCCATCTGCACCTCCAATGGAAGACAGGAAATTGTTAGATTTATAA 1353

FIG. 4D

```
Consensus --C-GC-GCTGAA-A-ATGTA--CTCA-ATGGGATTAGA-AC-AG-CCATCT---A--GA----GG-GGAAA-G--G 385
  Pet gag TGCTGCAGCTGAAAATATGTATTCTCAAATGGGATTAGACACTAGGCCATCTATGAAAGAAGCAGGTGGAAAAGAGG 385
     Bang TGCTGCAGCTGAAAACATGTATACTCAGATGGGATTAGACACCAGGCCATCTACAAGAGAAGCAGGAGGAAAAGAGG 385
JSY3 gag O TGCTGCAGCTGAAAATATGTACACTCAGATGGGATTAGACACTAGACCATCTATGAGAGAAGCAGGAGGAAAAGAGG 385
  UK8 gag TGCTGCAGCTGAAAATATGTATACTCAGATGGGATTAGACACTAGACCATCTACAAAGGAAGCTGGAGGAAAAGAGG 385
 Shizuoka  TACTGCCGCTGAAAATATGTATGCTCAGATGGGATTAGATACTAGACCATCTTTAAAGGAGGCAGGAGGAAAGGTAG 133
  Aomori 1 CACAGCAGCTGAAAATATGTATGCTCAGATGGGATTAGACACCAGACCATCTATAAAAGAAAGTGGGGGAAAAGAAG 133
   TM2 gag CACAGCAGCTGAAAATATGTATGCTCAGATGGGATTAGACACCAGACCATCTGTAAAAGAAAGTGGGGGAAAAGAAG 385
RT Forward ---------------------------------------------------------------------- 0
 RT Probe ---------------------------------------------------------------------- 0
RT Reverse ---------------------------------------------------------------------- 0
   FC1 GAG CGCAGCAGCTGAACACATGTATGCTCAGATGGGATTAGATACCAGACCATCTATAAAAGAAAGTGGGGGAAAAGAAG 385
      A9=4 ---------------------------------------------------------------------- 0
      B4=5 ---------------------------------------------------------------------- 0

Consensus A--G--CCTCCACAGGC-T-TCCTAT-CAAACA--AAATGGAG-ACCA-A--A-GTAGC-CT-GA-CC-AAAATGGT 462
  Pet gag AAGGC-CCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGTACCACAATATGTAGCACTTGACCCAAAAATGGT 461
     Bang AAAGC-CCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGCACCACAATATGTAGCACTTGACCCAAAAATGGT 461
JSY3 gag O AAAGC-CCTCCACAGGCATCTCCTATTCAAACAGCAAATGGAGCACCACAATATGTAGCACTTGACCCAAAAATGGT 461
  UK8 gag AAGGC-CCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGCACCACAATATGTAGCTCTTGACCCAAAAATGGT 461
 Shizuoka  A-GGAGCCTCCACAGGCATATCCTATCCAAACAATAAATGGAGCACCACAATATGTAGCCCTGGATCCTAAAATGGT 209
  Aomori 1 AAGGA-CCTCCACAGGCTTATCCTATTCAAACAGTAAATGGAGCACCACAGTATGTAGCCCTTGATCCAAAAATGGT 209
   TM2 gag AAGGA-CCTCCACAGGCTTATCCTATTCAAACAGTAAATGGAGCACCACAGTATGTAGCCCTTGATCCAAAAATGGT 461
RT Forward --AGC-CCTCCACAGGCATCTC---------------------------------------------------- 19
 RT Probe ----------------------ATTCAAACAGCAAATGGAGCACCACAATATG---------------------- 31
RT Reverse ------------------------------------------------------TTGACCCAAAAATGGT 16
   FC1 GAG AAGGA-CCTCCACAGGCTTATCCTATTCAAACAGTAAATGGAGCACCACAGTATGTAGCCCTTGACCCAAAAATGGT 461
      A9=4 -TAGC-CCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGTACCATAACACGTAGCACTTGACCCAAAAATGGT 75
      B4=5 --AGC-CCTCCACAGGCATATCCTATTCAAACAGTAAATGGAGTACCACAATATGTAGCGCTTGACCCAAAAATGGT 74
```

FIG. 10A

```
Consensus GTC-A-TTT-ATGGA-AA-GGAAGAGA-GG--TAGGAGG-GA-GA-GT-CA--T-TGGTT-AC-GC-TT-TC-GC-A 539
  Pet gag GTCCATTTTTATGGAAAAGGCAAGAGAAGGACTAGGAGGTGAGGAAGTTCAACTATGGTTTACTGCCTTCTCTGCAA 538
     Bang GTCCATTTTTATGGAAAAGGCAAGAGAAGGACTAGGAGGTGAGGAAGTTCAATTATGGTTTACTGCCTTCTCTGCAA 538
JSY3 gag O GTCCATTTTTATGGAAAAGGCAAGAGAAGGATTAGGAGGTGAGGAAGTTCAGCTATGGTTTACTGCCTTCTCTGCAA 538
   UK8 gag GTCTATTTTCATGGAAAAGGCAAGAGAAGGGTTAGGAGGTGAAGAAGTTCAACTATGGTTCACAGCCTTCTCTGCAA 538
 Shizuoka  GTCCATTTTTATGGAAAAAGCAAGAGAAGGATTAGGAGGAGAGGAGGTCCAACTATGGTTTACTGCATTTTCAGCTA 286
  Aomori 1 GTCCATTTTTATGGAGAAGGCAAGAGAGGGGCTAGGAGGTGAGGAGGTCCAACTGTGGTTCACAGCCTTTTCAGCTA 286
   TM2 gag GTCCATTTTTATGGAGAAGGCAAGAGAGGGGCTAGGAGGTGAGGAGGTCCAACTGTGGTTCACAGCCTTTTCAGCTA 538
RT Forward ---------------------------------------------------------------------------- 19
  RT Probe ---------------------------------------------------------------------------- 31
RT Reverse GTCCA------------------------------------------------------------------------ 21
   FC1 GAG GTCCATTTTTATGGAAAAAGCAAGAGAGGGGCTAGGAGGTGAGGAGGTCCAACTGTGGTTCACAGCCTTTTCTGCTA 538
      A9=4 G------------------------------------------------------------------------- 76
      B4=5 GTCCAA--------------------------------------------------------------------- 80

Consensus AT-TAAC--C-ACTGA-ATGGC-ACATTAAT-ATG-C-GC-CC-GG-TG-GC-GCAG-TAA-GA-AT--T-GA-GAA 616
  Pet gag ATTTAACACCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGCGCTGCAGATAAAGAAATATTGGATGAA 615
     Bang ATTTAACACCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGCGCTGCAGATAAAGAAATATTGGANGAA 615
JSY3 gag O ATTTAACACCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGCGCTGCAGATAAAGAAATATTGGATGAA 615
   UK8 gag ATTTAACACCTACTGACATGGCCACATTAATAATGGCCGCACCAGGGTGCGCTGCAGATAAAGAAATATTGGATGAA 615
 Shizuoka  ATCTAACATCAACTGATATGGCTACATTAATCATGTCTGCACCAGGTTGTGCAGCAGATAAGGAGATCTTAGATGAA 363
  Aomori 1 ATTTAACATCAACTGATATGGCTACATTAATTATGTCCGCACCTGGCTGTGCAGCAGTTAAAGAAATTCTAGATGAA 363
   TM2 gag ATTTAACATCAACTGATATGGCTACATTAATTATGTCCGCACCTGGCTGTGCAGCAGATAAAGAAATCCTAGATGAA 615
RT Forward ---------------------------------------------------------------------------- 19
  RT Probe ---------------------------------------------------------------------------- 31
RT Reverse ---------------------------------------------------------------------------- 21
   FC1 GAG ATTTAACTTCAACTGATATGGCTACATTAATTATGTCTGCGCCTGGCTGTGCAGCAGATAAAGAGATCTTAGATGAA 615
      A9=4 ---------------------------------------------------------------------------- 76
      B4=5 ---------------------------------------------------------------------------- 80
```

FIG. 10B